2Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002.CA Cancer J Clin,2005,55:74-108. 被引量：1
3Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.Neoadjuvant chemotherapy in invasive bladder cancer:update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.Eur Urol,2005,48:202-206. 被引量：1
4Raj GV,Karavadia S,Schlomer B,et al.Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle invasive bladder cancer.Cancer,2011,117:276-282. 被引量：1
5Fedeli U,Fedewa SA,Ward EM.Treatment of muscle invasive bladder cancer:evidence from the National Cancer Database,2003 to 2007.J Urol,2011,185:72-78. 被引量：1
6Grossman HB,Natale RB, Tangen CM,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med,2003,349:859-866. 被引量：1
7Chade DC, Laudone VP, Bochner BH, et al. Oncological outcomes after radical cystectomy for bladder cancer:open versus minimally invasive approaches.J Urol,2010,183:862-869. 被引量：1
8Herr HW.Extent of pelvic lymphnode dissection during radical cystectomy:where and why ! Eur Urol,2010,57:212-213. 被引量：1
9Paz-Ares LG,Solsona E,Esteban E,et al.Randomized phase Ⅲ trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC)to observation in patients with resected invasive bladder cancer:results of the Spanish Oncology Genitourinary Group (SOGUG)99/01 study.Proceedings of the 10th ASCO Annual Meeting,Chicago,USA,2010. 被引量：1
